

NMSGROUP

ONCOLOGY FORWARD

**NERVIANO
MEDICAL
SCIENCES**

ACCELERERA

NERPHARMA

SIMIS

NMS Group S.p.A. has approved the 2021 Financial Statements with positive outlook for 2022

Nerviano, 29 June 2022

The Board of Directors of NMS Group S.p.A has approved today the company's annual financial report, including the consolidated financial statements of the Group as of 31 December 2021.

"2021 was a challenging yet rewarding year for our Group. As we firmly believe in our mission to discover and develop life-changing molecules to patients, we are determined to relentlessly invest in time and resources in our five clinical assets (NMS-293 PARP/ NMS-088 FLP3/ NMS-153 MPS1/ NMS-812 PERK/ NMS-173 IDH1). We've set up the basis for a seamless collaboration with our new majority shareholder PAG, a leading Asia-Pacific focused alternative investment firm. PAG firmly believes in what we do and pledges to take our growth to the next level together. With our investors' full support, we have embarked an important transformation process to increase our performance. We have seen very positive changes at all levels, and we are convinced that we will deliver values to our new shareholder as well as to the patient population going forward," commented Barbara Marengo, CFO of NMS Group.

Key figures in 2021

- Cash position: cash and cash equivalent were €24.5 million as of 31 December 2021, compared to €35.6 million in 2020.
- Consolidated revenue was €40.2 million compared to €48.3 million in 2020. The difference was driven by the extraordinary milestone payment obtained in 2020.
- Nerviano Medical Sciences Srl (biotech company) confirmed the growth from the royalty streams of the two out-licensed products from €6 million in 2020 to over €10 million in 2021, with an investment of €27 millions in 2021 in our pipeline, approaching 70% of the consolidated revenue.
- Accelerera Srl (CRO) and NerPharMa (CDMO/CMO) confirmed their growth trends, reaching respectively in 2021 €16 million of revenues (€13 million in 2020) and circa €10 million (€8.9 million in 2020).
- Operative costs were just over €62.6 million compared to €55.6 million in 2020, representing the strong investment the group committed in oncology pipeline and in supporting CRO and CDMO activities.
- Net loss: €28.3 million compared to €17.7 million in 2020.

Outlook for 2022

With all the transformation activities initiated in 2022, we expect to see improvements across our 4 strategic dimensions: Financial, People, Transformation and Compliance.

###

NMSGROUP

ONCOLOGY FORWARD

**NERVIANO
MEDICAL
SCIENCES**

ACCELERERA

NERPHARMA

SIMIS

About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently Entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

The NMS Group has three subsidiaries. NMS Srl is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelerera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it